API
Call the NeuroLipid Foundation Model directly over a REST API.
AI.Lipids.Neurodegeneration.
The missing layer in neurodegeneration is lipid biology.
Cervolve was founded on a simple premise: understanding the biology of neurodegeneration requires us to understand brain lipids. We are building the models and datasets to map lipid biology across neurodegeneration and convert that biology into therapeutic insights.
The NeuroLipid Foundation Model
Our flagship model is the NeuroLipid Foundation Model, a multimodal foundation model trained to understand how lipids interact with proteins, and how those interactions shift across age and neurodegenerative disease.
Applications
01
Target identification & de-risking
Surface and prioritise lipid-linked targets, with the evidence to de-risk them early.
02
Drug repurposing
Reposition existing molecules by mapping their lipid-protein effects.
03
Patient stratification
Group patients by lipid biology to match the right therapy to the right person.
Access
Software
Use our applications: Target Discovery, Pocket Mapper, and Patient Stratification.
Agentic Workflow
Run autonomous research with the Cervolve Scientist agent, backed by the NeuroLipid Foundation Model.
Interested in learning more?
Contact us
Eamon Fitzgerald, PhD
Co-Founder, CEO
A neuroscientist with over 12 years of experience in genetics and lipid biology. He has authored 10 first-author publications in top-tier journals.
LinkedIn
Dylan Mann-Krzisnik, M.Eng/PhD
Co-Founder, CTO
An AI scientist with 8 years of experience in applied AI for life sciences. He earned his PhD at McGill University & Mila, where he developed state-of-the-art AI models for multi-omics and biological data integration.
LinkedInNews
June 2026
Cervolve at the BIO International Convention
We're heading to the BIO International Convention in San Diego in June 2026 to connect with partners across the life sciences.
May 2026
Longitude Prize on ALS Discovery Award winner
Cervolve, partnering with Espoir Bioscience and the EDDU at McGill, was named one of the Discovery Award teams selected from nearly 100 applications worldwide.
April 2026
Cervolve research published in Nature Communications
Cervolve and collaborators define a lipid-related mechanism in astrocytes of the prefrontal cortex that contributes to risk of major depressive disorder.
Read the paper
×
January 2026
Cervolve partners with Mila
Cervolve joined Mila, one of the leading AI institutes in the world, based in Montreal.